NO3102476T3 - - Google Patents
Info
- Publication number
- NO3102476T3 NO3102476T3 NO15710770A NO15710770A NO3102476T3 NO 3102476 T3 NO3102476 T3 NO 3102476T3 NO 15710770 A NO15710770 A NO 15710770A NO 15710770 A NO15710770 A NO 15710770A NO 3102476 T3 NO3102476 T3 NO 3102476T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898241P | 2013-10-31 | 2013-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3102476T3 true NO3102476T3 (no) | 2018-05-26 |
Family
ID=51982758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15710770A NO3102476T3 (no) | 2013-10-31 | 2015-03-18 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9492316B2 (no) |
| EP (5) | EP3669865A1 (no) |
| JP (2) | JP6482547B2 (no) |
| KR (1) | KR102307281B1 (no) |
| CN (2) | CN105682645B (no) |
| AU (3) | AU2014342017B2 (no) |
| BR (1) | BR112016009575B1 (no) |
| CA (1) | CA2926515C (no) |
| CL (1) | CL2016001041A1 (no) |
| CY (2) | CY1119961T1 (no) |
| DK (2) | DK3351239T3 (no) |
| ES (2) | ES2805880T3 (no) |
| HK (1) | HK1258014A1 (no) |
| HU (2) | HUE036554T2 (no) |
| IL (2) | IL244859B (no) |
| MX (2) | MX2016005508A (no) |
| MY (1) | MY177958A (no) |
| NO (1) | NO3102476T3 (no) |
| PH (1) | PH12016500767A1 (no) |
| PL (2) | PL3062775T3 (no) |
| PT (2) | PT3062775T (no) |
| RU (1) | RU2650614C2 (no) |
| SA (1) | SA516371022B1 (no) |
| SG (2) | SG11201603383VA (no) |
| SI (2) | SI3062775T1 (no) |
| TR (1) | TR201802759T4 (no) |
| UA (1) | UA119853C2 (no) |
| WO (1) | WO2015066548A1 (no) |
| ZA (1) | ZA201602556B (no) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| EP3412260B1 (en) | 2009-05-18 | 2020-08-26 | Dose Medical Corporation | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| CA2926515C (en) * | 2013-10-31 | 2020-11-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| WO2015085251A1 (en) * | 2013-12-06 | 2015-06-11 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
| AU2016230026B2 (en) | 2015-03-06 | 2020-07-09 | Envisia Therapeutics, Inc. | Implant applicators and methods of administering implants |
| CN108883070A (zh) | 2015-07-23 | 2018-11-23 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017015675A1 (en) * | 2015-07-23 | 2017-01-26 | Envisia Therapeutics, Inc. | Glaucoma treatment via intracameral ocular implants |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US9808531B2 (en) | 2015-09-22 | 2017-11-07 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| CN109561822B (zh) | 2016-05-31 | 2022-03-04 | 酷拉公司 | 可植入眼压传感器和使用方法 |
| CA3036993A1 (en) * | 2016-09-02 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Implant applicators |
| US20190192341A1 (en) * | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| CA3104468A1 (en) * | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a c-type natriuretic peptide compound, an natriuretic peptide receptor-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| US20200069577A1 (en) * | 2018-08-30 | 2020-03-05 | Yunxiang Liu | Ophthalmic formulations, process for preparing the same and method for administering the same |
| AU2019400857A1 (en) * | 2018-12-21 | 2021-08-12 | Re-Vana Therapeutics Ltd | Coated ocular implants |
| EP3969070A4 (en) * | 2019-05-13 | 2022-07-06 | University of Pittsburgh - of the Commonwealth System of Higher Education | POLYMER-BASED IMPLANT FOR RETINAL THERAPY AND METHODS OF MAKING AND USING THE SAME |
| CA3144406A1 (en) | 2019-06-27 | 2020-12-30 | Layerbio, Inc. | Ocular device delivery methods and systems |
| IL295357A (en) | 2020-02-06 | 2022-10-01 | Ocular Therapeutix Inc | Preparations and methods for the treatment of eye diseases |
| AU2021305247A1 (en) | 2020-07-10 | 2023-02-23 | Allergan, Inc. | Posterior chamber delivery device for sustained release implant |
| TW202216159A (zh) * | 2020-07-21 | 2022-05-01 | 美商歐樂根公司 | 具高負載前列腺素醯胺之眼內植入物 |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749776A (en) | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| CA1311686C (en) | 1986-06-25 | 1992-12-22 | John Weldon Shell | Controlled release bioerodible drug delivery system |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| CA2021316C (en) | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5834498A (en) | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| MY113268A (en) | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5545665A (en) | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5741810A (en) | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
| US6395787B1 (en) | 2000-02-08 | 2002-05-28 | Allergan Sales, Inc. | Ocular hypotensive lipids |
| US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US20040175410A1 (en) | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP4927298B2 (ja) | 2000-07-14 | 2012-05-09 | アラーガン、インコーポレイテッド | α−２−アドレナリンアゴニスト成分を含有する組成物 |
| EP1339438B1 (en) | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| EP1387671A1 (en) | 2001-05-03 | 2004-02-11 | MASSACHUSETTS EYE & EAR INFIRMARY | Implantable drug delivery device and use thereof |
| US20030220376A1 (en) | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| CA2496797C (en) | 2002-08-29 | 2012-01-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| US6899717B2 (en) * | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| EP1581181B1 (en) | 2002-11-06 | 2008-12-24 | ALZA Corporation | Controlled release depot formulations |
| US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) * | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20230026451A1 (en) * | 2004-04-30 | 2023-01-26 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050282902A1 (en) | 2004-06-22 | 2005-12-22 | Allergan, Inc. | Abnormal cannabidiols as agents for lowering intraocular pressure |
| US7101904B2 (en) | 2004-08-10 | 2006-09-05 | Allergan, Inc. | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US7473738B2 (en) * | 2004-09-30 | 2009-01-06 | Johnson & Johnson Vision Care, Inc. | Lactam polymer derivatives |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| CN101437478A (zh) * | 2004-10-04 | 2009-05-20 | Qlt美国有限公司 | 聚合送递制剂的眼部送递 |
| US7101906B2 (en) | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| CA2593661A1 (en) | 2005-01-14 | 2006-07-20 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions |
| PL1856042T3 (pl) | 2005-03-10 | 2012-11-30 | Allergan Inc | Podstawione gamma laktamy jako środki terapeutyczne |
| ATE515263T1 (de) | 2005-05-06 | 2011-07-15 | Allergan Inc | Substituierte beta-lactame und deren verwendung in der medizin |
| US8039507B2 (en) | 2005-06-29 | 2011-10-18 | Allergan, Inc. | Therapeutic substituted gamma lactams |
| DE102005033101A1 (de) | 2005-07-15 | 2007-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Resorbierbare Polyetherester und ihre Verwendung zur Herstellung von medizinischen Implantaten |
| CA2602440A1 (en) | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| US20090082321A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| US7863318B2 (en) | 2005-11-03 | 2011-01-04 | Allergan, Inc. | Prostaglandins and analogues as agents for lowering intraocular pressure |
| PE20080142A1 (es) | 2006-03-15 | 2008-04-14 | Boehringer Ingelheim Int | Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion |
| CA2645867A1 (en) | 2006-03-20 | 2007-09-27 | Allergan, Inc. | Substituted gamma lactams as prostaglandin ep2 agonists |
| US7439372B2 (en) | 2006-05-03 | 2008-10-21 | Allergan, Inc. | Therapeutic compounds |
| US7491844B2 (en) | 2006-05-04 | 2009-02-17 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
| US20070293873A1 (en) | 2006-06-19 | 2007-12-20 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US20070298073A1 (en) | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20080097335A1 (en) | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
| WO2009143288A1 (en) | 2008-05-20 | 2009-11-26 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100098772A1 (en) | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| CN104306103B (zh) * | 2009-01-23 | 2017-04-19 | 马缇医疗股份有限公司 | 一种或多种药剂的持续释放递送 |
| US20100247606A1 (en) | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| EP2512389B1 (en) | 2009-12-16 | 2015-09-02 | Allergan, Inc. | Intracameral devices for sustained delivery |
| EP2525776B1 (en) * | 2010-01-22 | 2015-10-28 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US20130071349A1 (en) * | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| KR20140028016A (ko) | 2011-04-22 | 2014-03-07 | 알러간, 인코포레이티드 | 통증을 치료하기 위한 지방산 아마이드 하이드롤라제 저해제 |
| WO2012149278A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Sustained release latanoprost implant |
| CA2926515C (en) * | 2013-10-31 | 2020-11-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US20190192341A1 (en) * | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| TW202216159A (zh) * | 2020-07-21 | 2022-05-01 | 美商歐樂根公司 | 具高負載前列腺素醯胺之眼內植入物 |
-
2014
- 2014-10-31 CA CA2926515A patent/CA2926515C/en active Active
- 2014-10-31 SG SG11201603383VA patent/SG11201603383VA/en unknown
- 2014-10-31 KR KR1020167013510A patent/KR102307281B1/ko active Active
- 2014-10-31 SI SI201430627T patent/SI3062775T1/en unknown
- 2014-10-31 RU RU2016116378A patent/RU2650614C2/ru active
- 2014-10-31 HU HUE14802985A patent/HUE036554T2/hu unknown
- 2014-10-31 ES ES17204626T patent/ES2805880T3/es active Active
- 2014-10-31 MX MX2016005508A patent/MX2016005508A/es active IP Right Grant
- 2014-10-31 US US14/529,526 patent/US9492316B2/en active Active
- 2014-10-31 SG SG10201800978UA patent/SG10201800978UA/en unknown
- 2014-10-31 WO PCT/US2014/063569 patent/WO2015066548A1/en active Application Filing
- 2014-10-31 DK DK17204626.0T patent/DK3351239T3/da active
- 2014-10-31 UA UAA201604694A patent/UA119853C2/uk unknown
- 2014-10-31 PL PL14802985T patent/PL3062775T3/pl unknown
- 2014-10-31 ES ES14802985.3T patent/ES2661666T3/es active Active
- 2014-10-31 TR TR2018/02759T patent/TR201802759T4/tr unknown
- 2014-10-31 MY MYPI2016000734A patent/MY177958A/en unknown
- 2014-10-31 AU AU2014342017A patent/AU2014342017B2/en active Active
- 2014-10-31 DK DK14802985.3T patent/DK3062775T3/en active
- 2014-10-31 EP EP20155608.1A patent/EP3669865A1/en not_active Withdrawn
- 2014-10-31 EP EP21200887.4A patent/EP4046628A1/en not_active Withdrawn
- 2014-10-31 EP EP24168728.4A patent/EP4406535A3/en active Pending
- 2014-10-31 CN CN201480059987.2A patent/CN105682645B/zh active Active
- 2014-10-31 SI SI201431594T patent/SI3351239T1/sl unknown
- 2014-10-31 PT PT148029853T patent/PT3062775T/pt unknown
- 2014-10-31 PT PT172046260T patent/PT3351239T/pt unknown
- 2014-10-31 EP EP17204626.0A patent/EP3351239B1/en active Active
- 2014-10-31 EP EP14802985.3A patent/EP3062775B1/en active Active
- 2014-10-31 JP JP2016527321A patent/JP6482547B2/ja active Active
- 2014-10-31 HU HUE17204626A patent/HUE050902T2/hu unknown
- 2014-10-31 CN CN201910745429.6A patent/CN110302138B/zh active Active
- 2014-10-31 BR BR112016009575-8A patent/BR112016009575B1/pt active IP Right Grant
- 2014-10-31 PL PL17204626T patent/PL3351239T3/pl unknown
-
2015
- 2015-03-18 NO NO15710770A patent/NO3102476T3/no unknown
-
2016
- 2016-04-03 IL IL244859A patent/IL244859B/en active IP Right Grant
- 2016-04-14 ZA ZA2016/02556A patent/ZA201602556B/en unknown
- 2016-04-25 PH PH12016500767A patent/PH12016500767A1/en unknown
- 2016-04-27 SA SA516371022A patent/SA516371022B1/ar unknown
- 2016-04-27 MX MX2020002381A patent/MX2020002381A/es unknown
- 2016-04-29 CL CL2016001041A patent/CL2016001041A1/es unknown
- 2016-11-14 US US15/350,471 patent/US9980974B2/en active Active
-
2018
- 2018-02-27 CY CY20181100242T patent/CY1119961T1/el unknown
- 2018-05-25 US US15/989,794 patent/US20180271878A1/en not_active Abandoned
-
2019
- 2019-01-10 HK HK19100383.4A patent/HK1258014A1/zh unknown
- 2019-02-12 JP JP2019022290A patent/JP6814829B2/ja active Active
- 2019-08-28 IL IL268976A patent/IL268976B/en active IP Right Grant
-
2020
- 2020-03-11 AU AU2020201778A patent/AU2020201778B2/en active Active
- 2020-03-27 US US16/832,700 patent/US20210030766A1/en not_active Abandoned
- 2020-06-25 CY CY20201100577T patent/CY1123077T1/el unknown
-
2021
- 2021-08-20 US US17/408,055 patent/US20220218721A1/en not_active Abandoned
-
2022
- 2022-02-04 AU AU2022200742A patent/AU2022200742B2/en active Active
-
2023
- 2023-08-09 US US18/231,955 patent/US20240108635A1/en active Pending